Decoding Multiple Sclerosis Through the Metabolome: Genetic Evidence for Causal Metabolic Pathways
Multiple sclerosis (MS) is a complex immune-mediated disorder characterized by inflammation, demyelination, and progressive neurodegeneration within the central nervous system. Although factors such as Epstein–Barr virus infection, smoking, obesity, and vitamin D deficiency have been associated with MS, the biological mechanisms connecting these exposures to disease remain incompletely understood. Metabolomics offers a particularly informative perspective because circulating metabolites reflect the combined activity of genetic, nutritional, immunological, and physiological processes. In a study published in the Journal of Neuroimmunology, Ge and colleagues investigated whether specific blood metabolites might contribute causally to MS rather than merely changing as a consequence of the disease.
Mendelian Randomization as a Natural Experiment
The researchers applied two-sample Mendelian randomization, a genetic epidemiology method that uses inherited genetic variants as proxies for modifiable biological exposures. Because genetic variants are assigned before disease development, this approach can reduce the influence of reverse causation and residual confounding that frequently affect conventional case–control studies. The analysis integrated metabolomic genome-wide association data from three cohorts, including up to 115,078 participants, with genetic data from 14,802 individuals with MS and 26,703 controls. As illustrated by the workflow on page 3, genetic instruments were selected, harmonized, and evaluated using several complementary statistical methods designed to detect heterogeneity, pleiotropy, and potentially influential variants.
A Metabolome-Wide Search Identifies 29 Candidates
Among 571 circulating metabolites examined, the study identified 29 with suggestive evidence of a causal relationship with MS risk. Six metabolites produced nominally significant and directionally consistent estimates under both genetic-instrument thresholds, whereas another 23 were significant under one threshold. The authors strengthened their analysis through sensitivity procedures including inverse variance weighting, MR-Egger regression, weighted median and weighted mode estimation, MR-PRESSO, and the MR Steiger directionality test. Although not every association remained statistically significant across all methods, the overall direction of the effects was generally consistent, supporting the prioritization of these metabolites for further investigation rather than establishing them as definitive clinical risk factors.
Lipoprotein Size May Matter More Than Conventional Labels
One of the most notable findings was that the relationship between circulating lipids and MS varied according to lipoprotein subclass. Genetically predicted cholesterol, phospholipids, and triglycerides within large very-low-density lipoprotein particles were associated with lower MS risk. By contrast, cholesterol, cholesterol esters, and phospholipids carried in very large high-density lipoprotein particles were associated with higher risk. The forest plot on page 4 highlights these contrasting effects. These results challenge the oversimplified classification of lipoproteins as uniformly “beneficial” or “harmful” and suggest that particle size, composition, and metabolic function may be more relevant to MS biology than total lipid concentrations alone.
Amino Acids Connect Metabolism, Immunity, and Myelin
Several amino acids also emerged as potential contributors to MS susceptibility. A genetically predicted one-standard-deviation increase in serine was associated with approximately 56% higher odds of MS, while lysine and O-sulfo-L-tyrosine were associated with more modest increases in risk. Serine is biologically compelling because it contributes to the synthesis of phosphatidylserine and sphingomyelin, lipids that are important components of myelin. The article also notes that Epstein–Barr virus can stimulate serine uptake and biosynthesis in B cells, providing a possible mechanistic connection between viral infection, immune-cell metabolism, and MS development. Nevertheless, the authors emphasize that circulating amino-acid concentrations observed after diagnosis may differ according to disease subtype, relapse status, and treatment.
Ketone Bodies and Uridine Reveal an Energy-Metabolism Paradox
Acetoacetate and acetone displayed some of the largest estimated effects: genetically predicted increases in either metabolite were associated with more than twice the odds of MS. Uridine, a metabolite involved in nucleotide and energy metabolism, was also positively associated with disease risk. The detailed plots on page 5 show the individual genetic estimates, combined causal models, and leave-one-out analyses for serine, acetoacetate, and acetone. These findings are particularly intriguing because elevated ketone bodies may represent either a pathogenic metabolic state before disease onset or a compensatory response after neurological injury. Consequently, evidence that ketogenic interventions may benefit some people with established MS should not be interpreted as proof that lifelong elevation of specific ketone bodies is protective.
From Genetic Prioritization to Clinical Translation
This study provides a systematic map of metabolic pathways that may participate in MS development, highlighting lipid transport, amino-acid metabolism, nucleotide turnover, and cellular energy production. Its principal strength lies in using genetic instruments to move beyond observational correlation; however, important limitations remain. Horizontal pleiotropy cannot be excluded completely, several metabolites lacked sufficient genetic instruments, the analysis assumed linear lifelong effects, and all contributing datasets were restricted to individuals of European ancestry. The results therefore do not justify metabolite supplementation, dietary restriction, or immediate clinical testing. Instead, they establish a focused research agenda: validate these signals in diverse populations, determine when during the life course they act, clarify their effects across MS subtypes, and evaluate whether they can become reliable biomarkers or therapeutically actionable targets.
Disclaimer: This blog post is based on the provided research article and is intended for informational purposes only. It is not intended to provide medical advice. Please consult with a healthcare professional for any health concerns.
References:
Ge, A., Sun, Y., Kiker, T., Zhou, Y., & Ye, K. (2023). A metabolome-wide Mendelian randomization study prioritizes potential causal circulating metabolites for multiple sclerosis. Journal of neuroimmunology, 379, 578105.
